京新药业(002020) - 2018 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2018 was CNY 643,598,548.68, representing a 34.53% increase compared to CNY 478,411,667.28 in the same period last year[8] - Net profit attributable to shareholders was CNY 88,025,890.09, up 19.54% from CNY 73,639,019.29 year-on-year[8] - The net profit after deducting non-recurring gains and losses was CNY 78,248,681.20, reflecting a 22.49% increase from CNY 63,879,366.28 in the previous year[8] - Basic earnings per share rose to CNY 0.1196, a 3.82% increase from CNY 0.1152 in the previous year[8] - The estimated net profit attributable to shareholders for the first half of 2018 is expected to range between ¥186.99 million and ¥220.99 million, reflecting a growth of 10.00% to 30.00% compared to ¥169.99 million in the same period of 2017[24] Cash Flow and Assets - The net cash flow from operating activities decreased by 43.98% to CNY 50,109,446.25, down from CNY 89,451,853.07 in the same period last year[8] - Total assets at the end of the reporting period were CNY 4,973,718,351.44, a 1.42% increase from CNY 4,903,994,210.21 at the end of the previous year[8] Expenses - Sales expenses increased by 90.34% to CNY 21,000,000, primarily due to the growth in revenue[18] - Financial expenses surged by 378.84% to CNY 4,000,000, mainly due to increased exchange losses[19] - Income tax expenses rose by 46.83% to CNY 1,670,000, attributed to the increase in profit for the year[22] - The sales expenses increased significantly by 90.34%, reaching ¥211.12 million, up from ¥110.91 million[23] - Financial expenses surged by 379.84%, amounting to ¥4.23 million, compared to ¥0.88 million in the previous year[23] - The asset impairment loss decreased by 51.35%, totaling ¥0.36 million, down from ¥0.74 million[23] Business Operations and Outlook - The company is experiencing stable growth in its main business operations, contributing to the positive profit outlook[24] - The company reported no overdue commitments from controlling shareholders or related parties during the reporting period[23] - There were no instances of non-operating fund occupation by controlling shareholders or related parties during the reporting period[25] - The company has engaged in investor relations activities, including an on-site investigation on March 13, 2018[26] - There were no violations regarding external guarantees during the reporting period[25] Return on Equity - The weighted average return on equity decreased by 0.83 percentage points to 2.22% from 3.05% in the previous year[8]